RGD Peptide–Albumin Conjugate for Endothelization of Electrospun Materials
- 作者: Cherepanova A.1,2, Akisheva D.1, Popova T.1,3, Chelobanov B.1,3, Chesalov Y.4, Godovikova T.1,3, Karpenko A.2, Laktionov P.1,2
-
隶属关系:
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences
- Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation
- Novosibirsk State University
- Boreskov Institute of Catalysis, Federal Research Center, Siberian Branch, Russian Academy of Sciences
- 期: 卷 45, 编号 6 (2019)
- 页面: 793-802
- 栏目: Article
- URL: https://journals.rcsi.science/1068-1620/article/view/229346
- DOI: https://doi.org/10.1134/S1068162019060116
- ID: 229346
如何引用文章
详细
To improve the endothelization of 3D matrices produced by electrospinning we propose adding cyclo(RGDfC) peptide conjugated to human serum albumin (HSA) (HSA-c(RGDfC)) to the electrospinning solution. HSA-c(RGDfC) has been prepared using a bifunctional linker with N-hydroxysuccinimide and maleimide groups, and the product has been confirmed by 1Н NMR spectroscopy. Electrospun matrices have been fabricated from the solutions of 3% polyurethane Tecoflex EG-80A with 10% HSA and 0.01–1.3% HSA–c(RGDfC) (relative to Tec) in 1,1,1,3,3,3-hexafluoro-2-propanol. The presence of HSA and the cyclo(RGDfC) peptide on the surface of electrospun matrices has been confirmed by FTIR spectroscopy. The structure of matrices has been examined by scanning electron microscopy. The ability of the matrices to facilitate the adhesion of primary human umbilical vein endotheliocytes (HUVECs) has been studied. The presence of HSA–c(RGDfC) conjugate in the matrices enhanced cellular adhesion in a dose dependent manner with a maximum effect at 1% HSA-c(RGDfC).
作者简介
A. Cherepanova
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation
编辑信件的主要联系方式.
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630055
D. Akisheva
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090
T. Popova
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Novosibirsk State University
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630090
B. Chelobanov
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Novosibirsk State University
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630090
Yu. Chesalov
Boreskov Institute of Catalysis, Federal Research Center, Siberian Branch, Russian Academy of Sciences
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090
T. Godovikova
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Novosibirsk State University
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630090
A. Karpenko
Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630055
P. Laktionov
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation
Email: a_cher@niboch.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630055